Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of BAY 86-6150 in hemophilia A or B with inhibitors
2011-000323-33Phase 2Terminated
- Sponsor
- Bayer
- Start
- May 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of BAY86-6150 in hemophilia A and hemophilia B (HB) (3 arms), sponsored by Bayer. Primary endpoint: Successful treatments of bleeding episodes. Started May 2012; status: terminated.
02
Drugs
BAY86-6150
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2011-000323-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000323-33.